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Abstract Regulators of G protein signaling RGS4 and RGS7
accelerate the kinetics of K+ channels (GIRKs) in the Xenopus
oocyte system. Here, via quantitative analysis of RGS expres-
sion, we reveal biphasic effects of RGSs on GIRK regulation. At
low concentrations, RGS4 inhibited basal GIRK activity, but
stimulated it at high concentrations. RGS7, which is associated
with the G protein subunit GL5, is regulated by GL5 by two
distinct mechanisms. First, GL5 augments RGS7 activity, and
second, it increases its expression. These dual effects resolve
previous controversies regarding RGS4 and RGS7 function and
indicate that they modulate signaling by mechanisms supple-
mentary to their GTPase-activating protein activity. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Regulator of G protein signaling (RGS) proteins accelerate
hydrolysis of GTP bound to the GK subunits of heteromeric
G proteins thereby promoting the formation of the inactive
GKGDPLQ heterotrimer, and hence act as negative regulators
of G protein-mediated signaling pathways [1^4]. The RGS
protein family includes more than 30 members, all of them
characterized by a homologous V120 amino acid region,
known as the RGS domain, that is responsible for binding
GK and GTPase-activating protein (GAP) activity [5,6]. A
subfamily of RGS proteins that includes RGS6, 7, 9, and
11, has two additional unique domains: the DEP domain
(disheveied/egl-10/pleckstrin) of an unknown function, and
the GGL (G protein Q-like) domain that has been shown to
direct a speci¢c interaction with the G protein subunit GL5
[7^9]. RGS6, RGS7 and RGS9 were puri¢ed or co-immuno-
precipitated from brain and retina only in complex with GL5
suggesting that these RGSs and GL5 only exist as hetero-
dimers in vivo [10,11]. Complexes of GL5 with RGS7 and
RGS9 serve as GAPs toward certain GK subunits [12].
Much of our knowledge about the coupling of RGS pro-
teins to Gi=o proteins under physiologic conditions has been
derived from the studies of G protein-activated K channels
(GIRKs). These channels are activated by direct binding of
the LQ subunits of G proteins, GLQ , normally released upon
activation of Gi=o [13^17]. Deactivation kinetics of neuro-
transmitter-evoked GIRK currents depend on sequestration
of free GLQ by GKGDP and, therefore, re£ect the rate of
GTP hydrolysis by GK [18]. Coexpression of RGS proteins
with Gi=o-coupled neurotransmitter receptors and GIRK
channels in Xenopus oocytes accelerates the deactivation of
GIRK channels [19^21]. Activation is accelerated as well, pos-
sibly also as a consequence of the increased GTPase activity,
though other factors might be involved [21]. Thus, GIRK
current is a sensitive indicator of the RGS activity, and these
channels have been extensively utilized to study the roles and
physiological e¡ects of RGS proteins. Surprisingly, coexpres-
sion of RGS proteins does not decrease (and sometimes in-
creases) the amplitude of agonist-evoked GIRK currents, in
contrast to what is predicted from their GAP action
[19,20,22,23]. The exact mechanism underlying this phenom-
enon remains unknown [4]. Recently, Kovoor et al. [21] used
the GIRK assay to explore the e¡ect of GL5 on the RGS7
function and demonstrated that GL5 enhances the RGS7-in-
duced acceleration of deactivation of GIRK. Coexpression of
GL5 did not change the amount of RGS7 in the oocytes, and
it was concluded that the sole e¡ect of RGS^GL5 interaction
is the enhancement of RGS GAP activity. Another line of
evidence supporting the role for GL5 as a stimulator of
RGS7 GAP activity is the ¢nding that GL5 enhanced the
inhibitory e¡ect of RGS7 on Gq-mediated Ca2 signaling in
transfected CHO cells [10]. However, in contrast to ¢ndings of
Kovoor et al., Witherow et al. [10] observed 5^10-fold in-
crease in RGS7 expression in the presence of GL5. In line
with the latter study, GL5L disappears from photoreceptors
of RGS9 knockout mice [24], supporting the view that the
presence of RGS9 improves biosynthesis or slows down deg-
radation of GL5.
In this report we attempted to resolve the apparent con£ict
regarding the e¡ect of GL5 on RGS7 expression through a
series of experiments titrating the amount of RGS7 expressed
in Xenopus oocytes. We demonstrate that GL5 has a dual
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e¡ect: (i) increase of RGS7 level, which was only observed at
submaximal expression of RGS7, and (ii) stimulation of
RGS7 e¡ect on GIRK kinetics observed at all levels of
RGS7 expression. Titration of the expression of another
RGS protein, RGS4, which we initially used as a control
for RGS7, helped us to resolve another controversy: previous
results of Doupnik et al. in Xenopus oocytes [19], showing a
decrease in basal GIRK current upon addition of RGS4, were
at odds with the increase observed by Bunemann and Hosey
in mammalian cells [25]. Here we show that RGS4 can be
both inhibitory or stimulatory, depending on its concentra-
tion. Thorough analysis of the protein levels not only helps
to avoid discrepancies arising from the use of di¡erent heter-
ologous expression systems and experimental protocols, but
also provides additional evidence that the RGS proteins have
functions in addition to their GAP activity.
2. Materials and methods
2.1. cDNA constructs and mRNA
The cDNAs were prepared as described in the previous publica-
tions: muscarinic 2 receptor (m2R) [26]; GIRK1 and GIRK2 subunits
of the GIRK channel [27]. The coding sequences of the cDNAs of the
RGS4 and RGS7 were ampli¢ed by polymerase chain reaction with
primers containing the desired restriction sites and inserted into high-
expression oocyte vectors containing 5P and 3P untranslated sequences
of Xenopus L-globin. The use of these vectors usually improves pro-
tein expression in the oocytes [28,29]. RGS4 was subcloned into XbaI/
HindIII sites of the pGEMHE vector [28], and bovine RGS7 was
inserted into the NotI/HindIII sites of the pBS-MXT vector [29].
The cDNA of the mouse GL5 was inserted into the NotI/HindIII sites
of the pBS vector (Stratagene). mRNAs were synthesized according to
a standard procedure which gives high-quality RNA with preferable
capping at the 5P end [30]. For electrophysiological and biochemical
experiments, the following amounts of RNA were injected (per oo-
cyte): GIRK1, GIRK2, m2R, 100 pg; GL5, 20 ng.
2.2. Oocytes and electrophysiology
Xenopus oocytes were prepared and injected as described [30], in
accordance with the instructions of Tel Aviv University Institutional
Animal Care and Use Committee. After injection, the oocytes were
incubated for 3 days at 20^22‡C in ND96 solution (96 mM NaCl,
2 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 5 mM HEPES, pH 7.5)
supplemented with 2.5 mM Na-pyruvate and 50 Wg/ml gentamicin.
Two-electrode voltage clamp experiments were performed as de-
scribed [26]. For measuring the GIRK1/2 currents, the oocytes were
placed in a V70 Wl chamber constantly perfused with ND96. The
holding potential was set at 380 mV. Basal (IhK) and acetylcholine
(ACh)-evoked (IACh) currents were measured in the hK solution (96
mM KCl, 2 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES,
pH 7.4^7.5). The perfusion allowed exchange of solution in the bath
within V0.5 s.
2.3. Immunochemistry
The oocytes were homogenized on ice in homogenization bu¡er
(20 mM Tris, pH 7.4, 5 mM EGTA, 5 mM EDTA, 100 mM NaCl)
containing the Roche Molecular Biochemicals protease inhibitor mix-
ture. Debris was removed by centrifugation at 8000Ug for 15 min at
4‡C [31]. Protein samples (¢ve oocytes per lane) were separated on
10% polyacrylamide^sodium dodecyl sulfate gels. RGS7 and GL5 ex-
pressed in the oocytes were monitored by Western blotting as de-
scribed [32]. Antibodies against RGS7 and GL5 were described pre-
viously [8,33] and used here at 1:3000 dilution. Visualization of
protein bands was performed using ECL reagents obtained from
Pierce, Inc. The intensity of labeling was quanti¢ed using the TINA
software (Raytest, Straubenhardt, Germany).
2.4. Statistical analysis
Data are presented as mean þ S.E.M. Comparison between two
groups of treatment was done using the two-tailed Student test or,
when appropriate, the paired t-test. Comparison between several
groups of data has been performed using one-way analysis of variance
(ANOVA) followed by Student^Newman^Keuls test.
3. Results
3.1. Regulation of basal activity of GIRK by RGS proteins
depends on their expression level
Xenopus laevis oocytes were injected with the RNAs of
GIRK1 and GIRK2 subunits (GIRK1/2) of the GIRK chan-
nel, the m2R, and di¡erent combinations of RGS7 and GL5.
The ion currents were measured using the two-electrode volt-
age clamp technique. The basic protocol is shown in Fig. 1A.
The oocyte was placed in a low-K solution (ND96), in which
the GIRK currents are negligible. Shifting to a high-K solu-
tion (hK) caused the appearance of a large inward current
(IhK) that re£ects the basal activity of the GIRK channels
[34]. After the basal currents reached a plateau, 10 WM ACh
was applied, to monitor the ACh-evoked current, IACh. After
V1 min in ACh, the agonist was washed out with hK solu-
tion containing 10 WM atropine (a muscarinic antagonist).
The speed of deactivation of ACh-evoked response was used
as the assay for RGS7 activity. For comparison, we also ex-
pressed RGS4, whose e¡ects on GIRK are well characterized
[19,21,25].
To characterize and compare the e¡ects of RGS4 and
RGS7 at di¡erent expression levels, oocytes were injected
with standard amounts of RNAs of GIRK1, GIRK2 and
m2R (0.1 ng/oocyte) and with increasing amounts of RGS7
or RGS4 RNAs. Fig. 1A presents an example of the e¡ect of
RGS4 and RGS7 on GIRK currents in oocytes obtained from
one donor (‘batch’). In agreement with previous ¢ndings [19^
22], coexpression of either RGS accelerated both activation
and deactivation of IACh. In addition, RGS4 a¡ected the am-
plitudes of basal and agonist-evoked currents, but we noticed
that the e¡ects varied as a function of the level of RGS4
expression. Thus, at all doses of injected RGS4 RNA, we
usually observed a decrease in the amplitudes of IhK and
IACh, whereas after longer periods, especially at the highest
doses used (5 or 10 ng RNA/oocyte), both IhK and IACh
were often increased. Fig. 1B compares the changes in ampli-
tudes of IhK (left panel) and IACh (right panel) at the lowest
RNA doses (0.05 and 0.2 ng/oocyte) and the highest doses
used (5 and 10 ng). We compared current amplitudes 3 days
after RNA injection (black bars) vs. the time when the en-
hancing e¡ect of 5^10 ng RNA was maximal (4 days in two
oocyte batches, 7 days in one batch). This comparison reveals
a striking change in the pattern of RGS4 e¡ect: the initial
decrease in current amplitudes observed after 3 days of pro-
tein expression disappears at later times, and (at higher doses)
is replaced by an increase. It is natural to assume that this
trend is a result of an increase in the level of RGS4 protein
expression. This assumption is further strengthened by the
observation that low RGS4 doses still inhibited IhK and
IACh on the same days when the high doses already produced
a maximal enhancement of the currents. This can be deduced
from Fig. 1B but is best seen in Fig. 1C which reports the
dose-dependency of RGS4 e¡ects in the full range of RNA
doses used. Currents were measured, in each oocyte batch, at
the same day when 5 or 10 ng RNA produced a maximal
enhancement (day 4 or day 7 after RNA injection). A statis-
tically signi¢cant (25^40%) reduction in IhK was observed at
two of the three lowest doses of RGS4 RNA used, 0.05 and
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0.5 ng/oocyte (Fig. 1C, left panel). This decrease was replaced
by a clear increase which reached 24 þ 6% at 10 ng RNA
(n = 20; P6 0.05; one-way ANOVA). The agonist-evoked
current, IACh, clearly showed the same tendency though the
increase was more pronounced. The decrease was seen only at
0.5 ng RNA/oocyte, and a signi¢cant increase was observed at
2^10 ng RNA, reaching s 50% at 5 and 10 ng (Fig. 1B, right
panel). These data resolve the present controversy concerning
the e¡ect of RGS4 on basal GIRK activity [19,25] and imply
that coexpression of RGS4 a¡ects GIRK in two di¡erent
ways.
The e¡ect of RGS7 on IhK and IACh resembled that of
RGS4, but the changes were smaller. A trend to decrease
was seen at low levels of expression; it tended to disappear
at higher doses of RGS7 (Fig. 1B). On average, under the
standard conditions used in the following experiments (0.05
and 10 ng RGS7 RNA, 4 days of expression), neither IhK nor
IACh was signi¢cantly changed at the fourth day in more than
10 oocyte batches examined (data not shown).
3.2. Dose-dependent acceleration of activation and deactivation
of IACh by RGS4 and RGS7
Activation and inactivation kinetics of the ACh-evoked
GIRK current could be approximately described by single
exponential functions [19] with time constants dactivation and
ddeactivation, respectively. Fig. 2 describes the dependence of
the changes in dactivation (Fig. 2A) and ddeactivation (Fig. 2B)
on the amounts of coinjected RNAs of RGS4 and RGS7.
Activation and deactivation of IACh were accelerated by
both RGS proteins, but RGS4 appeared to be more potent.
The e¡ects were quantitated by ¢tting the curves of d vs. RNA
dose to single exponential functions and calculating the e¡ec-
tive doses of RNAs at which the RGSs caused 50% e¡ect
(ED50) and the minimal (‘saturation’) values of d. Half max-
imal e¡ects of RGS4 on activation and deactivation occurred
at 0.25^0.33 ng RNA/oocyte, whereas those of RGS7 oc-
curred at 5^9-fold higher RNA concentrations. The maximal
acceleration was stronger in the presence of RGS4: 1.8 and
2.1 s for dactivation and ddeactivation, respectively, as compared
with 2.4 and 5.3 s for RGS7. The di¡erence in maximal e¡ects
suggests that, under the conditions of our experiments, RGS4
is a more potent GAP for Xenopus Gi=o proteins, which are
known to mediate the m2R-directed activation of GIRK in
this preparation [16].
3.3. Coexpression of GL5 stimulates both RGS7 protein levels
and its physiological e¡ect
The lowest concentration of RGS7 RNA causing a statisti-
cally signi¢cant change in ddeactivation was 0.5 ng/oocyte, while
at 10 ng/oocyte the e¡ect was almost maximal (Figs. 2 and 3).
Therefore, we chose these two concentrations to examine the
e¡ect of GL5 on RGS7. Since 0.5 ng RGS7 RNA/oocyte did
not result in a signi¢cant change in the rate of activation, we
monitored only the changes in deactivation. To describe the
Fig. 1. The e¡ects of RGS4 and RGS7 on the amplitude of GIRK1/2 currents depend on level of expression of RGS proteins. A: GIRK1/2
currents from oocytes coexpressing GIRK1/2 and m2R in the presence or absence of RGS4 (2 ng RNA/oocyte) or RGS7 (10 ng RNA/oocyte).
In the left panel, about 15^20 s in each record was omitted, to merge the beginnings of agonist washout. B: E¡ects of various doses of RGS4
on IhK and IACh 3 days after RNA injection (black bars; summaries from 5^17 cells of 1^3 batches) or 4^7 days after RNA injection (gray
bars; 10^28 cells from 2^3 batches). Pairwise comparisons of black and gray bars’ values were done using two-tailed t-test. *P6 0.05;
**P6 0.01. C: Dose-dependency of the e¡ects of RGS4 (b) and RGS7 (a) on the GIRK1/2 currents amplitude, after 4^7 days of expression
(RGS4) or 4 days (RGS7). Each experimental point represents results from 10^28 oocytes from two or three batches (RGS4) or 6^7 oocytes of
one batch (RGS7). In each oocyte, the amplitude of the current was normalized to the average amplitude in control group of the same batch.
The resulting normalized values were averaged from all oocytes. Asterisks indicate signi¢cant di¡erence from control (no RGS) at the P6 0.05
level.
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speed of deactivation, we used the time by which the deacti-
vation of IACh was 50% complete, t1=2 deactivation, to simplify the
analysis.
As shown previously [21], expression of GL5 alone (10 or 20
ng RNA/oocyte) did not exert a statistically signi¢cant e¡ect
on IACh, but enhanced the accelerating e¡ect of RGS7. As
expected, GL5 did not modify the e¡ect of RGS4 on GIRK
kinetics (data not shown), con¢rming that its e¡ect on RGS7
was speci¢c. We have ¢rst attempted to reproduce the data of
Kovoor et al. [21] who utilized high doses of RGS7 RNA.
Fig. 3A summarizes the results obtained in one such experi-
ment. Expression of 10 ng RGS7 RNA alone reduced
t1=2 deactivation by 45 þ 6% (Fig. 3A; changes in t1=2 deactivation
are shown as positive values). In agreement with the report
of Kovoor et al. [21], expression of GL5 further enhanced this
e¡ect 1.3-fold. It should be noted here that, since much faster
deactivation rate was observed with RGS4, the measured
speed of deactivation at high doses of RGS7 with GL5 was
not limited by our perfusion system (see Section 2). Impor-
tantly, when the amount of RGS7 expressed in the oocytes
was low (0.5 ng RNA/oocyte), GL5 enhanced the RGS7 e¡ect
in a more dramatic manner, from 14.5 þ 3.7% to 29 þ 2.4%
(i.e. about 2-fold; Fig. 3B). This result implied that GL5 could
enhance the action of RGS7 by more than one mechanism.
To examine whether expression of GL5 in£uences the
amount of RGS7 in the oocyte, either 0.5 or 10 ng/oocyte
of RGS7 RNA was injected in the presence or absence of
20 ng RNA of GL5. Western blot analysis was used to mon-
itor protein levels. Uninjected oocytes did not show detectable
endogenous RGS7 or GL5 (Figs. 4 and 5). Fig. 4 shows the
results of measurements of RGS7 protein. Injection of 10 ng
RNA gave approximately 3-fold higher RGS7 protein level
than 0.5 ng (Fig. 4A, upper panel). GL5 did not alter the
amount of RGS7 in oocytes that expressed the high amount
of RGS7 (summary of three experiments is shown in the lower
panel of Fig. 4A). This is in agreement with a previous report
Fig. 3. GL5 enhances the e¡ect of RGS7 on deactivation of IACh. Changes in t1=2 deactivation (% of control) are shown at the Y axes. The oocytes
coexpressed GIRK1/2 with m2R in the presence or absence of GL5 and di¡erent doses of RGS7. The bars show mean þ S.E.M., n = no. of oo-
cytes. In A, the oocytes were injected with 10 ng/oocyte RGS7 RNA. Results from one oocyte batch are shown. Similar results were obtained
in another batch of oocytes. In B, the oocytes were injected with 0.5 ng/oocyte RGS7 RNA. Data from three batches are summarized. Aster-
isks above bars indicate statistically signi¢cant di¡erences (*P6 0.05; **P6 0.01).
Fig. 2. The e¡ect of RGS4 and RGS7 on the kinetics of GIRK1/2 currents. The calculated (¢tted) values of ED50 and of the minimal d are
shown near each curve. The data were obtained in oocytes of one batch (5^6 oocytes at each RNA concentration). A: Dose^response of RGS7
and RGS4 e¡ects on dactivation of IACh. B: Dose^response of RGS7 and RGS4 e¡ects on ddeactivation of IACh.
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by Kovoor et al. [21], who also injected 10 ng RGS7 RNA per
oocyte. However, when the dose of RGS7 RNA was 0.5 ng/
oocyte, GL5 signi¢cantly increased the amount of RGS7
(191 þ 27% of control, n = 8 experiments; Fig. 4A). An in-
crease in the amount of RGS7 by coexpression of GL5 was
also observed at 2 ng RGS7 RNA/oocyte (data not shown).
Western blot analysis was further used to examine whether
other participants of GIRK1/2 activation pathway can alter
the level of the expressed RGS7. RGS7 (at 0.5 ng RNA/oo-
cyte) was coexpressed with GL5, GIRK1/2 and m2R in di¡er-
ent combinations (Fig. 4B). We found that the main factor
that increased the level of RGS7 expression was GL5 (1.9-
fold). Coexpression of m2R alone did not signi¢cantly alter
the level of RGS7 which was 123 þ 17% of control (n = 3; Fig.
4B). Coexpression of GIRK1/2 together with m2R also did
not lead to changes in the level of RGS7 (130 þ 9%, n = 4,
Ps 0.05). On the average, coexpression of m2R also did not
substantially alter the e¡ect caused by GL5 alone (Fig. 4B).
On the other hand, when GIRK1/2 and m2R were coex-
pressed along with GL5 and RGS7, the amount of RGS7
protein further rose to 291 þ 4% of control (n = 3). This di¡er-
ence was statistically signi¢cant compared with the e¡ect of
GL5 alone (P6 0.05 using the ANOVA test). However, fur-
ther statistical analysis by paired t-test in the three experi-
ments where both groups were present (RGS7+GL5 vs.
RGS7+GL5+GIRK+m2R) did not show a signi¢cant di¡er-
ence in RGS7 levels (P = 0.256). Therefore, we conclude that
GL5 is the main factor that causes the observed increase in
RGS7 levels, although the presence of all the components of
the signaling pathway, including the receptor and the e¡ector,
may potentiate the e¡ect of GL5.
We have also sought for a possible reciprocal e¡ect of
RGS7 on the expression of GL5. The control group contained
oocytes in which GL5 was expressed at the same level as in the
electrophysiological experiments (20 ng RNA/oocyte). The
amount of expressed GL5 protein was not altered by coex-
pression of either RGS7 (0.5 ng; 110 þ 8% of control, n = 6
experiments), GIRK1/2 (103 and 130% of control, n = 2), m2R
(102 þ 3%, n = 4), m2R+GIRK1/2 (93 and 121% of control,
n = 2), or RGS7+GIRK1/2 (85 and 122% of control, n = 2).
However, joint expression of RGS7 with m2R, with or with-
out the channel, produced a signi¢cant increase in the amount
Fig. 4. Expression of RGS7 protein in oocytes and the e¡ect of coexpression of GL5, m2R and GIRK. Upper panels show the Western blots
from representative experiments, and the bars in the lower panels below summarize the amount of RGS7 protein in oocytes, calculated from
densitometric analyses of the images. The bars show mean þ S.E.M., n = no. of experiments. A: Comparison of the e¡ect of coexpression of
GL5 on the protein level of RGS7 at low (0.5 ng RNA/oocyte) and high (10 ng RNA/oocyte) levels of RGS7. B: Western blot analysis of 0.5
ng/oocyte RGS7 RNA coexpressed with di¡erent combinations of GIRK1/2, m2R and GL5. Asterisks above bars indicate statistically signi¢-
cant di¡erences, at P6 0.05, from control (0.5 ng/oocyte RGS7 RNA alone) by one-way ANOVA test followed by Student^Newman^Keuls
test.
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of GL5 (P6 0.05 by one-way ANOVA; Fig. 5). The presence
of all the components of the pathway had the most consistent
impact on the protein level of GL5 (a 46 þ 2% increase above
control). Both ANOVA and paired t-test con¢rmed that the
concomitant presence of m2R and GIRK1/2 signi¢cantly im-
proved the e¡ect of RGS7 (P = 0.021, three experiments). An
improvement of RGS7 e¡ect by m2R alone was less obvi-
ous. Although the ANOVA test performed on the total sum-
mary of all experiments showed P6 0.05, paired t-test
comparison of the two groups of interest (GL5+RGS7
vs. GL5+RGS7+m2R) in three experiments where both
were present did not show a signi¢cant di¡erence (P = 0.19,
n = 5).
4. Discussion
GIRK1/2 channels mediate the inhibitory e¡ects of many
neurotransmitters [16,17]. They are widely distributed in the
brain, and their expression overlaps with that of RGS7 [22].
Since RGS7 regulates GIRK currents [21,22], and in native
tissues it is associated with GL5 [11,33,35], the analysis of
RGS^GL5 interaction is important for understanding regula-
tion of GIRK currents in vivo. The use of heterologous ex-
pression systems yielded con£icting results, hindering further
progress. The present study resolves the controversy and es-
tablishes a dual e¡ect of GL5 on RGS7: both protein levels
and the GTPase activity of RGS7 are increased by GL5.
4.1. Dual e¡ects of RGS proteins of GIRKs
This study was initiated to characterize the in£uence of GL5
on RGS7 expression and its GAP activity in Xenopus oocytes,
and in an attempt to understand the reasons for the contro-
versy over the question whether GL5 a¡ects the expression of
RGS7 [10,21]. We were able to demonstrate a dual e¡ect of
GL5 on RGS7. As assayed by monitoring the rate of deacti-
vation of agonist-induced GIRK current, GL5 augments the
e¡ect of RGS7, perhaps by stimulating its GAP action. In
addition, when the protein level of RGS7 is submaximal,
GL5 increases RGS7 expression. In the course of the study,
as a control for RGS7, we used the much better studied and
structurally less complicated RGS protein, RGS4. From these
experiments we realized that RGS4 had a dual e¡ect on the
basal activity of the GIRK channel which depended on the
dose of the expressed RGS4. Furthermore, RGS7 showed a
similar trend. The very notion of the possibility that RGS4
would have a dual e¡ect on the amplitude of GIRK currents
in the same cell, depending on the expression levels of partic-
ipating proteins, is not trivial. The same is true regarding the
e¡ect of GL5 on RGS7. By resolving the existing controver-
sies, our ¢ndings present a step forward in the understanding
of mechanisms of action and of the physiological roles of
RGS proteins and of GL5.
Basal activity of GIRK depends on the presence of free GLQ
arising due to basal activity of G proteins [16]. Being a GAP,
an RGS is expected to increase the fraction of GK proteins in
their GDP-bound form which sequesters GLQ , leading to a
decrease in IhK (the basal current). Such a decrease by
RGS1, 2, 3 and 4 has indeed been reported by Doupnik et
al. [19] in Xenopus oocytes. However, an opposite e¡ect was
observed in human embryonic kidney cells expressing GIRK
and RGS4 [25]. Bunemann and Hosey [25] proposed that
RGS has an additional action: occlusion of GLQ binding to
GKGDP, which results in a net increase in free GLQ concentra-
tion and thus a ‘constitutive’ activation of GIRK. Our data
show that both the inhibition and stimulation can be observed
at di¡erent expression levels of RGS in a single expression
system, resolving the controversy between the results obtained
by the two groups [19,25]. The resolution of this question also
has important mechanistic implications regarding the ways in
which RGS may regulate GIRK channels. The dose-depend-
ency of the two opposing e¡ects of RGS (Fig. 1B) supports
the Bunemann^Hosey hypothesis. The decrease in IhK, asso-
ciated with the GAP activity, requires lower levels of RGS4 or
RGS7. This corresponds to the high a⁄nity of binding of
RGS to the transition, short-lived state of GK (GTP-bound,
in the process of hydrolysis) [1,36]. On the other hand, RGS
binds to the GKGDP form of GK with low a⁄nity; thus, higher
doses of RGS are needed to e¡ectively compete with GLQ . This
is in line with the increase in IhK observed at high expression
levels of RGS4. While we have not observed a consistent
increase in IhK at higher doses of RGS7, this could be due
Fig. 5. Expression of GL5 protein in oocytes and the e¡ect of coex-
pression of RGS7, m2R and GIRK. GL5 was coexpressed along
with di¡erent combinations of GIRK1/2 (0.1 ng RNA/oocyte), m2R
(0.1 ng RNA/oocyte) and RGS7 (0.5 ng RNA/oocyte). The bars of
the lower panel summarize the amount of GL5 protein in oocytes,
calculated from densitometric analyses of the images. The bars
show mean þ S.E.M., n = no. of experiments. Asterisks above bars
indicate statistically signi¢cant di¡erences from control (the amount
of protein measured from oocytes that expressed GL5 alone) at
P6 0.05 level (one-way ANOVA followed by Student^Newman^
Keuls test).
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to a weaker coupling of this RGS to the relevant GK, or to a
limited saturating expression level (see below).
4.2. GAP activity of RGS proteins vs. their e¡ects on the
amplitude of agonist-evoked currents
As expected, RGS4 and RGS7 accelerated activation and
deactivation of agonist-evoked GIRK current, IACh. For each
RGS, the dose-dependencies of changes in activation and de-
activation of IACh were almost identical. In case of RGS4,
both kinetic e¡ects were observed already at a low dose of
this protein, coinciding with the GAP-related decrease in the
basal GIRK currents. This supports the idea that the accel-
eration of the activation is the consequence of the same mech-
anism as the acceleration of the deactivation, i.e. increased
GTPase rate of GK [19^21].
On the other hand, RGS7 did not reduce the amplitude of
the agonist-evoked current, IACh. Low levels of RGS4 de-
creased IACh, but caused an increase at higher expression lev-
els, instead of the decrease predicted from their GAP action.
An increase, or at least the absence of a decrease of the ago-
nist-evoked GIRK currents by coexpressed RGS proteins, has
been observed in all previous studies and remains unexplained
(see Section 1). The GAP action of RGS also cannot explain
the absence of a negative shift in the dose-dependency of the
response to agonist [19,20]. Therefore, additional mechanisms
of RGS action must be sought for. Unlike the change in IhK,
the increase in the amplitude of IACh cannot be explained by
the Bunemann^Hosey hypothesis. The argument is as follows:
after application of the agonist, the rate of GDP/GTP ex-
change at GK is greatly increased [37,38], and a substantial
fraction of GK would be in the GTP-bound form. Binding of
RGS4 to GKGDP is expected to have a much smaller impact
on the amplitude of IACh than on IhK. However, our data
show even greater increase in IACh than in IhK at all RGS
doses (Fig. 1B). This can be explained by the following alter-
native mechanisms. (i) RGS proteins may promote the for-
mation of complexes between GPCRs and GK proteins (e.g.
[39]), and this may lead to an improved response to agonist.
(ii) We have previously reported inhibition of GLQ -activated
GIRK by certain GTPQS-activated GK subunits [40,41]. Bind-
ing of RGS to GKGTP can oppose the interaction of GK with
the e¡ector [42] and thus reduce the inhibitory e¡ect of GK.
(iii) Recently, RGS4 was reported to interact with GIRK1/4
channels directly [43]. Such an interaction could in principle
improve GIRK activation by GLQ . Understanding why, de-
spite the accelerated deactivation rate, RGS proteins do not
induce reduction in signal magnitude is an important chal-
lenge for the future.
RGS4 has a stronger maximal e¡ect on deactivation of IACh
than RGS7, with saturation reached at lower levels of injected
RNA (Fig. 1), suggesting that RGS4 has a stronger GAP
activity, as in the case of RGS8 vs. RGS7 [22]. This is in
line with the results of biochemical measurements of GAP
activities of RGS4 and RGS7^GL5 complex toward GKo
[12]. However, at present it is not clear whether the maximal
e¡ect of any of the RGS proteins tested so far in the oocyte
re£ects the actual limit in GAP activity or is limited by max-
imally attainable level of their expression.
4.3. Dual regulation of RGS7 by GL5
When GIRK is used to assay the e¡ects of RGS proteins,
the acceleration of IACh deactivation is considered to be a
straightforward indicator of their GAP activity [19,21]. We
¢nd that GL5 enhances this e¡ect of RGS7 at all expression
levels of the latter. When the level of expression was such that
RGS7 produced its maximal physiological e¡ect (10 ng RNA/
oocyte), GL5 moderately but reproducibly enhanced the
RGS7-induced acceleration. Parallel biochemical experiments
showed no change in the amount of RGS7 protein in the
oocyte, implying that the observed acceleration of deactiva-
tion was due to an improvement of GAP activity of RGS7.
These data are in full agreement with the results of Kovoor et
al. [21], who also used 10 ng RNA/oocyte in their biochemical
experiments. However, we found that the enhancement of
RGS7-induced acceleration was substantially stronger when
the expression level of RGS7 was low, at 0.5 ng RNA/oocyte.
At this level, RGS7 alone only marginally increased the rate
of deactivation of IACh (half inactivation time was changed by
V14.5%), and GL5 enhanced this action 2-fold. This increase
of GL5 e⁄ciency appears to be almost completely attributed
to the increase in the amount of RGS7 protein (Fig. 4). The
latter result is in line with the report of Witherow et al. [10] in
mammalian cells. We think that GL5 is unable to further
increase RGS7 expression at a high RGS7 level because of a
certain limiting feature of the oocyte, such as saturation of its
RNA translation or protein processing machinery [44]. It is
not possible at present to compare the levels of RGS7 expres-
sion attained by RNA injection in oocytes vs. DNA trans-
fection in mammalian cells. It is possible that mammalian cells
also have an upper limit of RGS7 expression but it was not
reached by transient transfection [10].
It is still unclear why in oocytes GL5 enhances the GAP
action of RGS7 ([21] and this report) whereas pull-down as-
says with in vitro translated proteins show that GL5 inhibits
GK^RGS7 binding [8]. It is likely that additional proteins, e.g.
the e¡ector, present in the cell determine the functional out-
come of RGS7^GL5 interaction. A crucial role for the e¡ector
in determining whether GL5L would reduce or enhance the
GTPase activity of RGS9 has been recently demonstrated [45].
4.4. Mutual e¡ects of GL5 and RGS7
It is often observed that proteins that form a stable com-
plex, e.g. subunits of ion channels, increase each other’s ex-
pression [46]. RGS7 and GL5 are found in tightly associated
form in neuronal tissue [10,11], and they have been shown to
a¡ect the expression of each other in mammalian cells. In
accordance with these studies, our current experiments show
that GL5 can enhance RGS7 expression. Our data also show
that RGS7 increases the expression of GL5, however this ef-
fect was statistically signi¢cant only when other participants
of the signal transduction pathway, the m2 receptor and the
e¡ector, were coexpressed together with RGS7. In the absence
of RGS7, m2R and GIRK themselves did not have this e¡ect
(Fig. 5). Interestingly, the expression of RGS7 was a¡ected in
a similar way by the receptor and e¡ector, with the amount of
RGS7 increasing as much as 3-fold upon joint coexpression of
GL5, GIRK1/2 and m2R. Since in our electrophysiological
experiments both GIRK1/2 and m2R were always present, it
is very likely that the enhancement of RGS7 levels by GL5
contributed a major part of the total physiological e¡ect at
low doses of RGS7 RNA.
In all, our results indicate the existence of two separate
e¡ects of GL5 on RGS7: an enhancement of the GAP activ-
ity, and a control of protein level. They also suggest that the
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control of protein levels of GL5 and RGS7 is reciprocal, a
phenomenon not reported previously. A plausible mechanism
by which formation of bi- or multiprotein complexes could
increase the levels of participating proteins is the prevention
of degradation. Using pulse-chase methodology, Witherow et
al. demonstrated that in mammalian COS-7 cells separately
expressed RGS7 and GL5 are degraded more than 10-fold
faster than the RGS7^GL5 complex [10]. Such a mechanism
is also involved in regulation of RGS7 levels by polycystin
[47], and in co-regulation of GL and GQ levels whereby non-
complexed subunits are proteolytically degraded [48,49]. Fi-
nally, the additional increases in RGS7 and GL5 levels in the
presence of m2R and GIRK support the notion of the exis-
tence of a signaling complex containing the GPCR, G protein,
RGS and e¡ector [39], which could improve the biosynthesis
of participating proteins or protect them from degradation.
4.5. The advantages of Xenopus oocytes for quantitative studies
of expressed proteins
It is well known that proteins overexpressed in heterologous
systems may have non-speci¢c e¡ects and/or display promis-
cuous coupling to their targets. One way to assess the specif-
icity of interactions is monitoring and controlling the expres-
sion level of the proteins under study. Such a controlled
expression is easily accomplished with high accuracy in Xen-
opus oocytes by changing the amount of injected RNA (e.g.
[50]). Each RNA-injected cell expresses the protein, unlike in
transfection methodologies which leave a large percentage of
cells untransfected. In addition, this system provides almost
unlimited possibilities for combining various protein mes-
sages. The levels of protein in the whole cell, cytosol or in
plasma membrane can be monitored biochemically [31,51]. In
our hands, the variability of the expressed ion channel cur-
rents in oocytes from one batch is low. Variability between
batches can be reduced by using oocytes of the same size,
same number of days after RNA injection and amount of
RNA, and accounted for by repeating the same experiment
in several oocyte batches. Utilization of these precautions and
advantages allowed us to resolve two recent controversies re-
garding regulation of GIRK by RGS proteins, one as for the
e¡ect of RGS4 on basal GIRK activity, and the other con-
cerning the e¡ect of GL5 on expression of RGS7. Both con-
troversies appeared, on the ¢rst glance, to arise from the use
of di¡erent heterologous expression systems: mammalian cell
lines vs. Xenopus oocytes. Intuitively, because mammalian
proteins have been studied, one would gather that the mam-
malian cells reveal the ‘real’ e¡ects. However, the present
work shows that the di¡erences in both cases were in fact
quantitative, and the obtained data in all works re£ected fun-
damental features of the proteins under study, independent of
the expression system.
The results of this study further our understanding of the
function of RGS7 and RGS4 and of the regulation of RGS
proteins containing the GGL domain by GL5. A key corollary
of our ¢ndings is the importance of expression levels of inter-
acting proteins in heterologous expression systems. This dic-
tates both thorough monitoring of expression levels of partic-
ipating proteins, and testing the functional impact of changes
in protein levels.
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